Rakovina Therapeutics Expands Private Placement to $3 Million, Leveraging AI for Cancer Drug Discovery

Rakovina Therapeutics Increases Private Placement Offering

Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company focused on developing novel cancer therapies, has announced a significant increase in its private placement offering. Initially set at $1.25 million, the offering has been upsized to $3 million due to strong investor interest 1

1

2

3

Offering Structure and Terms

The private placement is structured as units priced at $0.06 each. Each unit consists of one common share and one warrant to purchase an additional common share at $0.10, exercisable for 24 months. Rakovina retains the right to accelerate the warrant exercise period if the 20-day volume-weighted average price of its shares exceeds $0.30 1

1

Utilization of AI in Drug Discovery

A key aspect of Rakovina's strategy involves leveraging artificial intelligence for cancer drug discovery. The company plans to use the proceeds to advance novel cancer treatments through collaborations with two proprietary AI platforms:

1. Deep Docking™ AI platform
2. Variational AI Enki™ Platform

These AI-driven approaches aim to accelerate the drug discovery process and identify potential best-in-class candidates 1

1

3

Recent Developments and Financial Results

Rakovina has reported progress in its AI-driven drug discovery efforts. The company's executive chairman, Jeffrey Bacha, stated that the Deep Docking AI platform has successfully generated a focused shortlist of potential best-in-class PARP-1 inhibitor candidates capable of crossing the blood-brain barrier 3

3

For the third quarter of 2024, Rakovina reported:

• Net loss: $1,015,667 for the quarter, $2,588,630 for the nine months ended September 30, 2024
• Research and development expenses: $678,299 for the quarter, $1,597,067 for the nine months
• General and administrative expenses: $268,909 for the quarter, $796,183 for the nine months 4

  4

Related Stories

Renovaro Secures $15M Funding and Announces Merger with BioSymetrics to Advance AI-Driven Cancer Diagnostics and Therapies

Renovaro's AI-Driven Cancer Diagnostics Subsidiary Receives EU Funding and New Leadership

Breakthrough Oncology Research Fuels Multibillion-Dollar Opportunities in Cancer Therapies

Perimeter Medical Imaging AI Announces C$13.5M Private Placement for Cancer Detection Technology

Future Plans and Investor Confidence

The increased private placement reflects strong investor confidence in Rakovina's approach to cancer drug development. The company plans to continue the development of its kt-3000 series through collaborations with biotech and pharma companies 1

1

2

Bacha expressed enthusiasm about the company's progress, stating, "Artificial intelligence is no longer just the future of drug development—it's the reality we're building today." He emphasized that the additional funds will be crucial in unlocking transformative opportunities in 2025 4

4

Regulatory Considerations

The private placement is subject to regulatory approvals, including acceptance from the TSX Venture Exchange. The securities will be subject to a four-month plus one day resale restriction from the date of issue 1

1

2

As Rakovina Therapeutics continues to integrate cutting-edge AI with its laboratory infrastructure at the University of British Columbia, the increased funding positions the company to potentially accelerate its innovative cancer therapy platform development in the coming year.